Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 3 trial

MLA

Linong Ji, et al. “Efficacy and Safety of Janagliflozin Monotherapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Diet and Exercise: A Multicentre, Randomized, Double‐blind, Placebo‐controlled, Phase 3 Trial.” Diabetes, Obesity and Metabolism, vol. 25, Jan. 2023, pp. 1229–40. EBSCOhost, https://doi.org/10.1111/dom.14971.

APA

Linong Ji, Xiaozhen Jiang, Qingshun Hao, Zhifeng Cheng, Kun Wang, Shuguang Pang, Meiying Liu, Yushan Guo, Xiaowen Chen, Xiuhai Su, Tao Ning, Jie Liu, Fang Bian, Yulan Li, Zhinong Zhang, Weihong Song, & Jingfang Sun. (2023). Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 3 trial. Diabetes, Obesity and Metabolism, 25, 1229–1240. https://doi.org/10.1111/dom.14971

Chicago

Linong Ji, Xiaozhen Jiang, Qingshun Hao, Zhifeng Cheng, Kun Wang, Shuguang Pang, Meiying Liu, et al. 2023. “Efficacy and Safety of Janagliflozin Monotherapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Diet and Exercise: A Multicentre, Randomized, Double‐blind, Placebo‐controlled, Phase 3 Trial.” Diabetes, Obesity and Metabolism 25 (January): 1229–40. doi:10.1111/dom.14971.